Skip to main navigation

About
Pipeline
Products
- DEXTENZA^® (dexamethasone ophthalmic insert)
  - Postsurgical Ocular Inflammation and Pain
  - Ocular Itching Associated with Allergic Conjunctivitis
- ReSure® Sealant
Investors
Investor Relations
Careers
Search

Press Releases

Keyword Search

Year

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

March 06, 2023

Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference

February 28, 2023

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results

February 21, 2023

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

February 11, 2023

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

January 06, 2023

Shareholder Tools

Print
E-mail
RSS
Share
Alerts
Contact

X

Share on:
Facebook
Twitter
LinkedIn

Privacy Policy | Terms of Use

The use of this Site is governed by its Terms of Use. The information contained in this Site is for informational purposes only. It is not a substitute for professional medical advice and should not be used to diagnose or treat any medical or health condition.

The contents of this Site are subject to change without notice. Ocular Therapeutix may modify and/or discontinue operation of all or portions of this Site at any time at its sole discretion without notice, and assumes no responsibility to update this Site. Ocular Therapeutix makes no representations or warranties with respect to the use of this Site or any information obtained herein.